(PharmaNewsWire.Com, November 03, 2017 ) The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. A new study, focusing on the Hepatitis E virus (HEV) infection, and latest ongoing clinical trials for the treatment of hepatitis E has been publicized to the wide repository of Market Research Hub (MRH). The study is titled as “Hepatitis E Global Clinical Trials Review, H2, 2017”, which provides top-line data relating to the clinical trials on Hepatitis E. Additionally, report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The clinical trials presented in the study are collated from 80+ different clinical trial registries, conferences, journals, news etc. across the world.
Presently, Hepatitis E is an important public health concern in many developing countries, causing waterborne outbreaks as well as sporadic autochthonous hepatitis. Hepatitis E is a liver disease caused by the Hepatitis E virus (HEV). It has been analyzed that Hepatitis E is preventable by vaccination, but there is currently no vaccine available for protection against hepatitis E infection. Ribavirin monotherapy is the treatment of choice for patients chronically infected with HEV. In the past decade, multiple clinical trials have been carried out for the development of new treatments. This paper will focus on current clinical trials and recent therapies on specific target involved in Hepatitis E virus. Overall, the report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, endpoints status and sponsor type. In terms of geographical presence, top countries contributing to clinical trials for Hepatitis E include Asia-pacific, Europe and G7 & E7 countries. The above-detailed information supports buyers in an understanding of trials count and enrollment trends by country in global hepatitis E therapeutics market.
Moving further, to present a detailed assessment of the competition prevailing in the hepatitis E clinical trials, the report profiles companies along with their recent launch activity and innovation, and enlists all trials (Trial title, Phase, and Status) pertaining to the company. Key players involved in the clinical trials are Xiamen Innovax Biotech Co. Ltd., Xiamen Yangshengtang Biotechnology Co. Ltd., GlaxoSmithKline Plc., International Centre for Diarrhoeal Disease Research Bangladesh and Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
Additionally, the report also provides prominent drugs for in-progress trials, which is based on number of ongoing trials. The data presented in the study helps readers in identifying prominent locations for conducting clinical trials which saves time and cost.
Market Research Hub (MRH) is a next-generation reseller of pharmaceutical industry reports and analysis. MRH’s expansive collection of reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
